Aquestive Therapeutics (AQST) EBITDA: 2017-2025
Historic EBITDA for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to -$15.4 million.
- Aquestive Therapeutics' EBITDA fell 34.21% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$69.0 million, marking a year-over-year decrease of 96.00%. This contributed to the annual value of -$44.1 million for FY2024, which is 460.83% down from last year.
- According to the latest figures from Q3 2025, Aquestive Therapeutics' EBITDA is -$15.4 million, which was down 14.01% from -$13.5 million recorded in Q2 2025.
- In the past 5 years, Aquestive Therapeutics' EBITDA registered a high of $8.1 million during Q1 2023, and its lowest value of -$28.9 million during Q4 2021.
- For the 3-year period, Aquestive Therapeutics' EBITDA averaged around -$9.4 million, with its median value being -$11.5 million (2024).
- In the last 5 years, Aquestive Therapeutics' EBITDA skyrocketed by 161.03% in 2023 and then slumped by 465.55% in 2024.
- Over the past 5 years, Aquestive Therapeutics' EBITDA (Quarterly) stood at -$28.9 million in 2021, then surged by 57.33% to -$12.4 million in 2022, then spiked by 34.33% to -$8.1 million in 2023, then crashed by 110.27% to -$17.1 million in 2024, then tumbled by 34.21% to -$15.4 million in 2025.
- Its EBITDA stands at -$15.4 million for Q3 2025, versus -$13.5 million for Q2 2025 and -$22.9 million for Q1 2025.